Ukraine war latest: Russian glide bomb attack on Kramatorsk kills 3, including 13-year-old boy, governor says

Russian glide bomb attack on Kramatorsk kills 3, including 13-year-old boy, governor says * Pro-Ukrainian partisans disable electronic warfare equipment in Russia's ...
The Kyiv Independent

'Explosion in production area' — Ukraine confirms Flamingo missiles hit explosives plant in Russia's Samara Oblast

The Flamingo missile, built by controversial defense manufacturer Fire Point, has only been used by Kyiv on a handful of occasions since being first unveiled last summer, with its reported use ...
en.defence-ua

Ukrainian FP-5 Flamingo Missile Hits Plant of the Leading Explosives Manufacturer in russia (Video)

This is not the first time that Ukrainian long-range weapons have attacked Promsintez JSC, an important explosives manufacturer in the russian federation ...

Ukraine strikes Russian oil export hub

Ukraine has struck Russia’s largest western export terminal in an effort to stifle Moscow’s windfall from rising global oil ...
TMCnet

Greenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-01

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated ...

Greenwich LifeSciences Provides Update on Upcoming AACR Meeting

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated ...

Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01

Detailed price information for Greenwich Lifesciences Inc (GLSI-Q) from The Globe and Mail including charting and trades.
Targeted Oncology

GLSI-100 Vaccine Shows <1% Annual Recurrence Rate in Phase 3 Breast Cancer Trial

An open-label non–HLA-A*02 cohort showed a 0.7% annualized recurrence rate after primary immunization with GLSI-100, measured over an average 1.2 patient-years of exposure. Historical comparison to ...

Greenwich LifeSciences, Inc.: Greenwich LifeSciences Provides Update Showing Continued Reduction in Recurrence Rate in the Open Label Arm of FLAMINGO-01

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01 ...
The Manila Times

Greenwich LifeSciences Provides Update Showing Continued Reduction in Recurrence Rate in the Open Label Arm of FLAMINGO-01

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the 'Company'), a clinical-stage biopharmaceutical company focused on its Phase ...

Greenwich LifeSciences, Inc.: Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01 ...
The Manila Times

Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the 'Company'), a clinical-stage biopharmaceutical company focused on its Phase ...